

EADV 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success



EADV 2026



2026

EADV 2026 Preview – Table of Contents

• <u>New Trends in Dermatology Treatment At EADV'26</u>	3-5
• <u>Key Sessions To Watch</u>	6-7
• <u>Industry-sponsored Sessions & Focus Areas At EADV 2026</u>	8-17
• <u>Competitive Landscape At a Glance at EADV 2026</u>	9-10
• <u>Key Industry-sponsored Sessions At EADV 2026</u>	11-17
• <u>New Entrants</u>	18
• <u>AI/ML Trends & Strategic Watchpoints At EADV 2026</u>	19-21
• <u>AI / Digital Health Angle At EADV 2026</u>	20-21
• <u>What We're Watching For Post-congress</u>	22
• <u>Get In Touch With LucidQuest</u>	23



• **Atopic dermatitis differentiation is moving beyond mechanism choice**

- EADV 2026 will bring new data across IL-13, IL-18, IL-4R α , JAK and regulatory T-cell approaches, including zumilokibart/APG777, lunsekimig, EVO301, telikibart, lebrikizumab, dupilumab, abrocitinib and rezpegaldesleukin. The competitive question will be whether any approach separates on sustained response, difficult-to-treat sites, dosing frequency or treatment simplicity



• **Hidradenitis suppurativa is becoming a test of inflammatory versus fibrotic biology**

- Late-breaking data for tulisokibart, lutikizumab and abdakibart will sit alongside sessions examining TL1A, IL-1, IL-17, neutrophilic inflammation, fibroblast activation and tunnel-associated biology. The key question will be whether these mechanistic differences translate into clinically meaningful separation in deeper disease, tunnels, scarring or durability





- **Alopecia areata differentiation is shifting toward durable disease control**

- New data for bempikibart, ritlecitinib and baricitinib will address long-term response, adolescent treatment and whether regrowth can persist after treatment withdrawal. The key tension will be whether durability, treatment-free response or use in younger patients becomes more important than short-term SALT (Severity of Alopecia Tool) improvement alone



- **Symptom control is becoming a stronger differentiator across chronic inflammatory skin disease**

- EADV 2026 will feature new data in CSU and prurigo nodularis, including remibrutinib, an oral MRGPRX2 partial inverse agonist and 52-week oturkibart results. The question will be whether faster symptom relief, sustained itch control and treatment convenience become more important competitive differentiators as therapeutic options expand





• Oral psoriasis therapies are raising the efficacy bar

- EADV 2026 will feature 2-year icotrokinra data at high-impact sites and a direct oral comparison involving zasocitinib, alongside broader discussion of IL-23 and TYK2 strategies. The question will be whether oral therapies begin competing on deep and sustained skin clearance rather than convenience alone



• Vitiligo is moving toward a more clearly defined systemic-treatment market

- Longer-term upadacitinib data, including combination use with NB-UVB, and Phase 3 ritlecitinib results will bring systemic treatment into sharper focus. The competitive question will be how efficacy, durability, combination strategy and patient selection shape future treatment sequencing





Key Sessions To Watch (1/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
30 Sep 2026	Tulisokibart Phase 2b in moderate-to-severe HS	Late Breaking	Alexa B. Kimball	Will provide Phase 2b placebo-controlled efficacy and safety data for tulisokibart in adults with moderate-to-severe HS
30 Sep 2026	Oturkibart 52-week Phase 3 in prurigo nodularis	Late Breaking	Jianzhong Zhang	Presentation of 52-week data assessing sustained itch and lesion control with otkurtikibart
30 Sep 2026	Lutikizumab mechanism in hidradenitis suppurativa	Late Breaking	Johann Gudjonsson	Session will show how lutikizumab's effects on neutrophilic inflammation and fibroblast activation relate to clinical response in HS
30 Sep 2026	Zumilokibart/APG777 Phase 2 APEX Part B in AD	Late Breaking	Melinda Gooderham	Presentation will test whether a half-life-extended anti-IL-13 approach can combine efficacy with a less burdensome dosing strategy in a crowded AD landscape
01 Oct 2026	Ritlecitinib long-term efficacy through 5 years in alopecia areata	Late Breaking	Brett King	Will provide a long-term durability benchmark as alopecia areata competition moves beyond initial hair regrowth toward sustained disease control





Key Sessions To Watch (2/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
01 Oct 2026	Upadacitinib Week 76 ± NB-UVB in non-segmental vitiligo	Late Breaking	Julien Seneschal	Will show whether upadacitinib's efficacy and safety hold at Week 76 in adolescents and adults, and add data on combination use with NB-UVB phototherapy
01 Oct 2026	Abdakibart anti-IL-1 β Phase 2 LOTUS in HS	Late Breaking	Martina L. Porter	Will provide Week 16 Phase 2 efficacy and safety data for abdakibart, an anti-IL-1 β antibody, in moderate-to-severe HS, including results by IHS4 subgroup and lesion type
02 Oct 2026	Icotrokinra 2-year durability in high-impact-site psoriasis	Late Breaking	Richard B. Warren / Branchburg, US	Will show whether an oral targeted peptide can maintain control in difficult-to-treat psoriasis sites over two years, an important test of durability for oral therapy
02 Oct 2026	Zasocitinib vs deucravacitinib in plaque psoriasis	Late Breaking	Linda Stein Gold / Branchburg, US	Will provide a direct intraclass TYK2 benchmark, testing whether a newer oral agent can raise expectations for complete skin clearance without changing the oral safety proposition.

Industry-Sponsored Sessions & Focus Areas – EADV 2026





EADV 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
Oral systemic treatment expansion	Multiple	Icotrokinra, zasocitinib, upadacitinib, ritlecitinib, remibrutinib, oral MRGPRX2 partial inverse agonist	EADV 2026 will test whether oral therapies can compete on depth and durability of control as well as convenience, potentially raising expectations for systemic treatment across several dermatologic diseases
Durability and longer-term disease control	Multiple	Icotrokinra, ritlecitinib, oturkibart, upadacitinib, remibrutinib, bempikibart	Extended follow-up and off-treatment data will make sustained response and persistence of benefit increasingly important alongside initial efficacy
New mechanism differentiation	Multiple	TL1A / tulisokibart, IL-1 / lutikizumab and abdakibart, IL-7Rα / bempikibart, IL-13 / zumilokibart, MRGPRX2 targeting	The congress will test whether mechanistic novelty translates into clinically meaningful differentiation, rather than simply adding more targeted options to crowded treatment landscapes
Difficult-to-treat disease and sites	Multiple	High-impact-site psoriasis, HS lesion subtypes and tunnels, refractory urticaria, difficult-to-control inflammatory disease	These populations will provide a tougher test of differentiation and may reveal where therapies perform differently when conventional response measures are no longer enough



EADV 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
Treatment withdrawal, combination and treatment burden	Multiple	Bempikibart off-treatment response, upadacitinib ± NB-UVB, oral targeted therapies, extended-dosing approaches	EADV 2026 will broaden the discussion from whether treatments work to how long benefit lasts, whether combination therapy adds value and how much treatment patients need to maintain control
Real-world evidence and treatment persistence	Multiple	Remibrutinib, ritlecitinib, baricitinib, upadacitinib and established targeted therapies	Real-world and persistence datasets will test whether clinical-trial performance translates into routine practice, particularly for long-term effectiveness, tolerability and continued treatment use



Key Industry-Sponsored Sessions at EADV 2026 (1/7)



• **Pfizer:**

- Focus Areas: **Vitiligo, Atopic Dermatitis & Alopecia Areata**
- Pfizer will run separate sessions on **non-segmental vitiligo** and on **advanced systemic treatment in moderate-to-severe atopic dermatitis and severe alopecia areata**. The sessions will focus on disease assessment, identifying appropriate patients for systemic treatment, and translating advanced-treatment data into individualized care



• **Johnson & Johnson:**

- Focus Areas: **Psoriasis, IL-23 Biology & Earlier Treatment**
- Johnson & Johnson will focus on **innovation in psoriasis care**, including **IL-23 biology, earlier treatment and multidisciplinary management across skin and joint disease**. The sessions will examine whether **intervening earlier and treating beyond visible skin symptoms can improve longer-term disease control**



Key Industry-Sponsored Sessions at EADV 2026 (2/7)



• **Novartis:**

- Focus Areas: Hidradenitis Suppurativa, Psoriasis & CSU
- Novartis will focus on early recognition and individualized care in HS, early treatment and sustained control across skin and joint disease in psoriasis, and evolving CSU management with remibrutinib. The sessions will emphasize earlier intervention, treatment expectations and practical management in routine care



• **AbbVie:**

- Focus Areas: Psoriasis, Alopecia Areata & Atopic Dermatitis
- AbbVie will focus on selective IL-23 inhibition and head-to-toe control in psoriasis, evolving care in alopecia areata, and progress toward minimal disease activity in atopic dermatitis. Across these sessions, the emphasis will be on achieving deeper and more sustained disease control rather than relying on conventional response thresholds alone



Key Industry-Sponsored Sessions at EADV 2026 (3/7)



• **Eli Lilly:**

- Focus Areas: Alopecia Areata, Psoriasis & Obesity
- Lilly will present newly released baricitinib adolescent alopecia areata data and real-world evidence, alongside a separate symposium examining the relationship between psoriasis and overweight/obesity. The psoriasis session will also discuss the clinical relevance of concomitant ixekizumab and tirzepatide treatment from the TOGETHER-PsO study



• **Biogen:**

- Focus Areas: Cutaneous Lupus Erythematosus
- Biogen will focus on the clinical spectrum, pathobiology, patient burden and evolving therapeutic landscape of CLE. The session will examine how disease heterogeneity and unmet need could shape future treatment pathways



Key Industry-Sponsored Sessions at EADV 2026 (4/7)



• UCB:

- Focus Areas: Psoriasis, Hidradenitis Suppurativa & Palmoplantar Pustulosis
- UCB will focus on IL-17A/IL-17F biology and bimekizumab across psoriasis and HS, including earlier intervention and real-world decision-making. A separate session on palmoplantar pustulosis will focus on recognising PPP as a distinct and burdensome inflammatory disease



• Almirall:

- Focus Areas: Psoriasis & Atopic Dermatitis
- Almirall will focus on sustained psoriasis control beyond PASI and on visible disease burden, deep response and treatment simplicity with lebrikizumab in atopic dermatitis. The sessions will place greater emphasis on maintaining control and improving everyday treatment outcomes



Key Industry-Sponsored Sessions at EADV 2026 (5/7)



• Incyte:

- Focus Areas: Hidradenitis Suppurativa & Moderate Atopic Dermatitis
- Incyte will examine the HS journey from disease burden to emerging treatment approaches, while its AD symposium will focus on a new era in moderate disease management. The sessions will concentrate on areas where treatment pathways remain less clearly defined



• Galderma:

- Focus Areas: Atopic Dermatitis, Prurigo Nodularis & IL-31
- Galderma will focus on targeting the IL-31 neuroimmune pathway across atopic dermatitis and prurigo nodularis. The symposium will examine how this pathway contributes to disease and whether targeting it can improve treatment outcomes across both conditions



Key Industry-Sponsored Sessions at EADV 2026 (6/7)



• MSD:

- Focus Areas: Hidradenitis Suppurativa, Fibrosis & Immune Biology
- MSD will focus on immune-fibrotic cross-talk in HS, including how inflammatory mechanisms and fibroblast biology may influence treatment decisions. The session will connect emerging disease biology with practical clinical management rather than focusing only on symptomatic control



• Sanofi:

- Focus Areas: Hidradenitis Suppurativa & Long-Term Disease Management
- Sanofi will focus on the HS patient journey from diagnosis through treatment, with attention to disease burden, durable control and future treatment approaches. The session will examine how management may evolve as additional treatment options become available



Key Industry-Sponsored Sessions at EADV 2026 (7/7)



- **LEO Pharma:**

- Focus Areas: **Chronic Hand Eczema**
- LEO Pharma will focus on the **burden of chronic hand eczema** and approaches to improving care. The symposium will examine how better recognition and treatment can **address the impact of disease on patients' daily lives**



New Entrants

Asset / Company	2026 Presence
Oturkibart	Late Breaking: Efficacy and Safety of Oturkibart in Adults with Prurigo Nodularis: 52-Week Results from a Phase 3 Trial
Zumilokibart	Late Breaking: Efficacy and Safety of Zumilokibart (APG777), a Half-Life-Extended Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis: Primary Results From the Phase 2 APEX Part B Dose-Regimen-Finding Study
Bempikibart	Late Breaking: Bempikibart, a novel IL-7R α antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial
Daxdilimab	Late Breaking: Daxdilimab in Moderate-to-Severe Discoid Lupus Erythematosus: Efficacy and Safety Results from a Phase 2, Randomised, Placebo-controlled Trial
Lunsekimig	Late Breaking: Efficacy and safety of lunsekimig in moderate-to-severe atopic dermatitis: Results from the phase 2b VELVET trial
Tulisokibart	Late Breaking: A Phase 2b Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Adults With Moderate to Severe Hidradenitis Suppurativa
MG-K10	Late Breaking: Efficacy and Safety of MG-K10 Administered at 600 mg Every 8 Weeks Versus 300 mg Every 4 Weeks in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: Results of a Randomized Phase 2 Study
Lunsekimig	Late Breaking: Efficacy and safety of lunsekimig in moderate-to-severe atopic dermatitis: Results from the phase 2b VELVET trial







AI / Digital Health Angle at EADV 2026 (1/2)

- **AI and digital-health presentations at EADV 2026 will largely focus on diagnostic support, melanoma risk prediction, teledermatology and image-based assessment, rather than drug discovery or development. Sessions on AI in dermatology practice, teledermatology, 3D total-body photography and dermoscopic classification will test whether these tools can move from technical validation toward practical use in patient triage, diagnosis and longitudinal monitoring**
- **The most relevant signal will be whether AI-supported approaches can demonstrate value alongside dermatologist assessment rather than simply report standalone model accuracy. This will be particularly important in melanoma risk assessment, dermoscopy and teledermatology, where EADV 2026 will include direct comparisons with clinician decision-making and real-world service evaluation**
- **Key sessions include:**
 - AI strategies in dermatological practice
 - MELAPRED: A Parsimonious Clinical–Genetic Algorithm for Melanoma Risk Prediction
 - Comparison of a Vision Transformer AI Model and Dermatologists in Dermoscopic Image Classification



AI / Digital Health Angle at EADV 2026 (2/2)

- Results from the 2025 British National Teledermatology Standards Audit
- Making teledermatology work in 2026. Pinpointing the when and how.
- Is AI superior to traditional human-based decision-making? (Controversies)
- Playing with AI in dermatology (Workshop)
- ISD: Bridging the digital divide in global dermatology, promise, pitfalls and practical solutions
- From morphology to AI diagnosis
- Digital technologies: what's out there for psoriasis?
- The role of AI in dermatopathology
- eGEPARD as a Digital Self-Screening Tool to Support Early Detection of Psoriatic Arthritis in Psoriasis Patients
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - Melanoma risk prediction and earlier identification of high-risk patients
 - Dermoscopic image classification and diagnostic support
 - Teledermatology triage and remote specialist access
 - Digital monitoring through 3D total-body photography
 - Clinical workflow integration and dermatologist–AI collaboration



What We're Watching for Post-EADV 2026

- Whether **tulisokibart**, **lutikizumab** and **abdakibart** generate sufficient **clinical and mechanistic differentiation** to clarify the future roles of **TL1A** and **IL-1** targeting in **hidradenitis suppurativa**.
- Whether **zasocitinib** and **icotrokinra** strengthen the case for **oral psoriasis therapy** through **deeper skin clearance, durability and control of high-impact sites**, particularly given the **head-to-head TYK2** data planned for **zasocitinib**
- Whether **longer-term and treatment-withdrawal data** for **bempikibart**, **ritlecitinib**, **oturkibart** and **upadacitinib** establish **durability** as a stronger differentiator across **alopecia areata, prurigo nodularis and vitiligo**
- Whether **zumilokibart/APG777** and other emerging atopic dermatitis approaches demonstrate enough differentiation in **response durability and dosing strategy** to influence future treatment positioning in an **already crowded market**
- Whether **AI-focused datasets** including **MELAPRED, Vision Transformer dermoscopy, 3D total-body photography and teledermatology evaluations** provide evidence strong enough to support **integration into routine dermatology risk assessment, diagnosis and monitoring**

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM